ArticleJournal of cachexia, sarcopenia and muscle2026
Sarcopenia Predicts Outcome After Chemoimmunotherapy, Not Chemotherapy, in Advanced Lung Cancer: Single-Centre Retrospective Study.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal computed tomography body composition changes in patients receiving curative radiotherapy for non-small cell lung cancer.Physics and imaging in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSarcopenia, characterized by progressive loss of skeletal muscle mass, is prevalent in patients with non-small cell lung cancer (NSCLC). While sarcopenia has been associated with poor prognosis in multiple types of cancer, its predictive role in the context of first-line treatment combining PD-(L)1 inhibitors with platinum-based chemotherapy (CITx) remains unclear in advanced NSCLC.
methodsIn a single-centre retrospective cohort, patients with advanced NSCLC without actionable genomic alterations who received either CITx (n = 552) or platinum-doublet chemotherapy alone (CTx; n = 622) were analysed. Sarcopenia was defined on the Martin's computed tomography-derived skeletal muscle index definition. Progression-free survival (PFS) and overall survival (OS) were assessed. Interaction between sarcopenia and treatment modality was explored.
resultsSarcopenia was observed in 49.5% of patients. The presence of sarcopenia was associated with worse outcomes in overall patients (median OS: 9.4 vs. 11.4 months; HR 1.22, 95% CI 1.08-1.39). When stratified by treatment groups, sarcopenia was significantly associated with higher risk of progression (adjusted HR 1.23, 95% CI 1.01-1.49) and death (adjusted HR 1.42, 95% CI 1.16-1.74) in CITx-treated patients, whereas no such association was observed in the CTx group. The interaction between sarcopenia and treatment type was significant for both PFS (p = 0.041) and OS (p = 0.022).
conclusionsSarcopenia is a predictive biomarker for inferior outcomes in patients with advanced NSCLC treated with CITx, but not with CTx. Assessment of skeletal muscle mass can help identify patients at risk for suboptimal response to CITx. This study provides grounds for future exploration in interventions targeting sarcopenia and cachexia to enhance clinical outcomes in advanced cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.